FDA Reinstates NMN for Supplements: Medspas Eye Synergy with NAD+ Therapy and GLP-1 Symptom Relief

Green NMN supplement capsules spelled out on wooden background near pill bottle
The FDA has reversed its previous decision, making NMN legal again as a dietary supplement and expanding options for those interested in wellness and longevity.
Courtesy of mizina At Adobe Stock

In 2022, the FDA decided to revoke Nicotinamide Mononucleotide (NMN) from being marketed as a dietary supplement, declaring it needed to first undergo investigation as a new drug. On Sept. 29, three years later, however, the FDA amended its decision and ruled the drug as lawful to use in dietary supplements. Because this is a direct precursor, compared to other NAD+ precursors that must first be converted to NMN inside the cell to become NAD+, patients could see these supplements paired with the medical-grade NAD+ therapies they receive at medspas, and potentially alongside GLP-1 use.  

Therapies medspas currently offer for optimization of  NAD+ include nasal spray application, IV infusion and injectables. These coenzymes are shown to decrease with age and lead to age-related diseases—essential to convert food into energy and support cellular repair, DNA maintenance and overall metabolism. Many patients, including younger adults, are interested in boosting energy, cellular repair and longevity, making these treatments appealing as part of a proactive wellness trend occurring in medspas.

This article is only available to registered users.

Log In to View the Full Article

More in Treatments